Skip to content

Evaluation the efficiency of coenzyme Q10 (ubiquinone) supplementation on cisplatin-induced nephrotoxicity

Evaluation the efficiency of coenzyme Q10 (ubiquinone) supplementation on cisplatin-induced nephrotoxicity inpatients under chemotherapy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211205053287N1
Enrollment
46
Registered
2022-04-28
Start date
2022-04-21
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotoxicity due to cisplatin. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Intervention group: In 23 patients receiving cisplatin after checking the conditions for inclusion in the study, BUN, cr, GFR, Blood Group, Rh tests were checked and 60 Q10 tablets (pr

Sponsors

Shahre-kord University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1- Age between 80-20 years, 2- Do not take antioxidant and anti-inflammatory supplements for at least 1 month before the start of the study 3- Willingness to cooperate in the research project and completing the informed consent form Community Verified icon

Exclusion criteria

Exclusion criteria: 1- Changing the method of drug treatment and taking antioxidant and anti-inflammatory supplements during the study period 2- Changing lifestyle (changing diet, physical activity and level of mental stress) during the study

Design outcomes

Primary

MeasureTime frame
Nephrotoxicity due to cisplatin. Timepoint: In patients receiving cisplatin, the tests are checked once before starting (Q10) supplementation and once after supplementation (2 months later). Method of measurement: Check blood urea nitrogen (BUN) and creatinine (Cr) for patients.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mehrdad Sepehrnia

Shahre-kord University of Medical Sciences

dr.sepehrnia2008@yahoo.com+98 31 5549 2237

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026